ID   PER-403
AC   CVCL_C8YK
SY   Per403
DR   Wikidata; Q123033260
RX   PubMed=1785673;
RX   PubMed=17934517;
RX   PubMed=21447744;
RX   PubMed=23128391;
RX   PubMed=24518598;
RX   PubMed=29348827;
CC   Sequence variation: Gene fusion; HGNC; HGNC:13575; BRD4 + HGNC; HGNC:29919; NUTM1; Name(s)=BRD4-NUTM1, BRD4-NUT; Note=BRD4 exon 11 fused to NUTM1 exon 2 (PubMed=23128391; PubMed=24518598; PubMed=29348827).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Thoracic cavity; UBERON=UBERON_0002224.
DI   NCIt; C45716; NUT carcinoma
DI   ORDO; Orphanet_443167; NUT midline carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   11Y
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 19-12-24; Version: 3
//
RX   PubMed=1785673; DOI=10.1097/00043426-199124000-00011;
RA   Kees U.R., Mulcahy M.T., Willoughby M.L.N.;
RT   "Intrathoracic carcinoma in an 11-year-old girl showing a
RT   translocation t(15;19).";
RL   Am. J. Pediatr. Hematol. Oncol. 13:459-464(1991).
//
RX   PubMed=17934517; DOI=10.1038/sj.onc.1210852;
RA   French C.A., Ramirez C.L., Kolmakova J., Hickman T.T., Cameron M.J.,
RA   Thyne M.E., Kutok J.L., Toretsky J.A., Tadavarthy A.K., Kees U.R.,
RA   Fletcher J.A., Aster J.C.;
RT   "BRD-NUT oncoproteins: a family of closely related nuclear proteins
RT   that block epithelial differentiation and maintain the growth of
RT   carcinoma cells.";
RL   Oncogene 27:2237-2242(2008).
//
RX   PubMed=21447744; DOI=10.1158/0008-5472.CAN-10-3513; PMCID=PMC3070805;
RA   Schwartz B.E., Hofer M.D., Lemieux M.E., Bauer D.E., Cameron M.J.,
RA   West N.H., Agoston E.S., Reynoird N., Khochbin S., Ince T.A.,
RA   Christie A.L., Janeway K.A., Vargas S.O., Perez-Atayde A.R., Aster J.C.,
RA   Sallan S.E., Kung A.L., Bradner J.E., French C.A.;
RT   "Differentiation of NUT midline carcinoma by epigenomic
RT   reprogramming.";
RL   Cancer Res. 71:2686-2696(2011).
//
RX   PubMed=23128391; DOI=10.1038/onc.2012.487;
RA   Thompson-Wicking K., Francis R.W., Stirnweiss A., Ferrari E.,
RA   Welch M.D., Baker E., Murch A.R., Gout A.M., Carter K.W.,
RA   Charles A.K., Phillips M.B., Kees U.R., Beesley A.H.;
RT   "Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in
RT   NUT midline carcinoma.";
RL   Oncogene 32:4664-4674(2013).
//
RX   PubMed=24518598; DOI=10.1038/bjc.2014.54; PMCID=PMC3950881;
RA   Beesley A.H., Stirnweiss A., Ferrari E., Endersby R., Howlett M.,
RA   Failes T.W., Arndt G.M., Charles A.K., Cole C.H., Kees U.R.;
RT   "Comparative drug screening in NUT midline carcinoma.";
RL   Br. J. Cancer 110:1189-1198(2014).
//
RX   PubMed=29348827; DOI=10.18632/oncotarget.22862; PMCID=PMC5762512;
RA   Stirnweiss A., Oommen J., Kotecha R.S., Kees U.R., Beesley A.H.;
RT   "Molecular-genetic profiling and high-throughput in vitro drug
RT   screening in NUT midline carcinoma-an aggressive and fatal disease.";
RL   Oncotarget 8:112313-112329(2017).
//